Bank of America Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock

Posted by Brian Himes on Aug 11th, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective hoisted by research analysts at Bank of America from $30.00 to $32.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price target would indicate a potential upside of 4.69% from the stock’s previous close.

A number of other research firms also recently weighed in on HIMS. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. reduced their price objective on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Citigroup boosted their target price on Hims & Hers Health from $28.00 to $35.00 and gave the company a “neutral” rating in a research note on Thursday, July 23rd. Finally, TD Cowen upped their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $32.57.

Get Our Latest Research Report on Hims & Hers Health

Hims & Hers Health Stock Down 3.8%

HIMS traded down $1.20 during trading on Tuesday, hitting $30.57. 14,617,514 shares of the company’s stock were exchanged, compared to its average volume of 26,759,574. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The business’s 50 day moving average is $31.94 and its two-hundred day moving average is $26.07. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The stock has a market cap of $7.07 billion, a P/E ratio of -339.69, a PEG ratio of 88.90 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.20 EPS. As a group, equities analysts expect that Hims & Hers Health will post 0.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock in a transaction on Monday, July 6th. The shares were sold at an average price of $36.49, for a total value of $261,377.87. Following the transaction, the chief financial officer owned 284,321 shares in the company, valued at $10,374,873.29. This trade represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the transaction, the chief operating officer owned 432,124 shares in the company, valued at approximately $13,611,906. This represents a 3.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 83,126 shares of company stock worth $2,711,339 in the last ninety days. 11.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Versant Capital Management Inc increased its position in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after purchasing an additional 319 shares during the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health during the fourth quarter valued at $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the third quarter valued at $28,000. Finally, Bogart Wealth LLC boosted its position in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Second-quarter revenue increased 38% year over year to approximately $753.2 million, beating consensus estimates near $699 million. The company also cited strong subscriber growth and broader personalized-care offerings. Hims & Hers raises annual forecast revenue on strong subscriber growth
Positive Sentiment: Hims & Hers raised its 2026 revenue outlook to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, and projected third-quarter revenue of $880 million-$900 million, above analyst expectations. Hims & Hers Boosts Revenue Target, Swings to Second-Quarter Loss
Positive Sentiment: Management said artificial intelligence is improving customer engagement, while specialty-care expansion and international growth through Eucalyptus support longer-term demand. Needham raised its price target to $42 from $35 and maintained a Buy rating. HIMS Q2 Earnings Call Focuses on AI and Global Expansion
Negative Sentiment: The company reported a quarterly loss of about $0.37 per share, substantially worse than the roughly $0.05-$0.07 loss analysts expected and a profit in the year-earlier period. The miss was the primary reason investors sold the stock. Hims & Hers Q2 revenue beat offset by wider-than-expected loss
Negative Sentiment: Investments in branded GLP-1 weight-loss treatments, restructuring charges and international expansion are pressuring margins. Investors appear concerned that the costly weight-loss strategy could delay sustainable profitability despite rapid revenue growth. Hims & Hers shares slide as costly weight-loss push squeezes margins
Negative Sentiment: Several law firms announced investigations into potential securities-law violations or alleged breaches of fiduciary duty. These announcements may add reputational and potential litigation risk, although no wrongdoing has been established. Kaplan Fox investor investigation

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.